Gapping up
In reaction to earnings/guidance:
- DB +8.9%, BYD +6.3%, CALX +5.5%, TENB +5.5%, SHOP +5.3%, GOOG +5.1% (also co authorizes repurchase up to an additional $50 bln of Class C shares), AMD +4.7%, OLN +4.6%, NAVI +4.2%, YUMC +3.9%, SONY +3.9%, JNPR +3.8%, PPD +3.7%, MANH +3.7%, BSX +3.7%, EAT +3.6%, SWK +3.4%, CSTM +3.3%, EXTR +3.1%, CAMT +2.9%, ACCO +2.7%, MATX +2.6%, TECK +2.6%, MCO +2.6%, MDLZ +2.5%, APAM +2.4%, SNY +2.4%, COF +2.2%, MAS +2.2%, ALKS +2.2%, TER +2.1%, LYG +2.1%, TNL +2.1%, DAN +2.1%, TX +2%, HUM +2%, TKR +2%, V +1.8%, NCR +1.7%, IPG +1.7%, EIX +1.6%, EVR +1.5%, IART +1.5%, AVY +1.5%, TDY +1.5%, ROL +1.5%, SAIA +1.5%, YUM +1.4%, LBRT +1.2%, HES +1.2%, FEYE +1.1%, GD +1.1%, OC +1%, WNC +1%
Other news:
- ADMA +24.2% (FDA granted approval for the Company's expanded manufacturing process, enabling fractionation and purification of a 4,400-liter plasma pool for the manufacture of Intravenous Immune Globulin)
- UTL +9.6% (to be added to the S&P SmallCap 600)
- G +8% (to be added to the S&P MidCap 400)
- CDXC +5.4% (enteres into a strategic supply agreement with Health & Happiness Group)
- OII +4.7% (wins contracts in excess of $135 mln for Manufactured Products segment)
- GNW +4.2% (moving from the S&P MidCap 400 to the S&P SmallCap 600)
- EGY +3.7% (signs LOI with Omni Offshore Terminals)
- GRFS +3.6% (signed an agreement with the government of Andorra through Andorra Development and Investment to establish a global R+D+i hub to advance knowledge of the human immune system and investigate and develop new immune therapies)
- CYBE +3.3% (receives new order for its SQ3000 Multi-Function systems)
- HUM +2% (HUM to acquire remaining 60% interest in Kindred at Home for $5.7 bln)
- BGNE +1.9% (announces interim results from Phase 3 ALPINE trial comparing BRUKINSA vs ibrutinib in chronic lymphocytic leukemia)
- TRIL +1.8% (provides a data update, announced Phase 1b/2 program priorities across seven hematologic and solid tumor indications, and reported governance changes with its Board of Directors)
- FLXN +1.7% (to present preliminary data from Phase 1 trial of FX201)
- ARWR +1.3% (announces "positive" interim 48-week liver biopsy results from the AROAAT2002 study, an open-label Phase 2 clinical study of ARO-AAT)
- ETH +1.1% (declares special dividend of $0.75/sh)
Analyst comments:
- GSX +5.8% ( upgraded to Buy from Sell at Goldman)
- RL +2.5% (upgraded to Outperform from Market Perform at Cowen)
- MMC +1% (upgraded to Overweight from Neutral at Piper Sandler)
- ABB +0.5% (upgraded to Neutral from Underweight at JP Morgan)